This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Horizon Pharma (HZNP - Free Report) and Ligand Pharmaceuticals (LGND - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
LGNZZ LGND LGNYZ LGNXZ HZNP LGNDZ
After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front.
VVUS GLENMARK 532296 LGNZZ LGND LGNYZ LGNXZ LGNDZ BMRN GLKQY
After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. In the first four months of the year (January-April), the biotech industry significantly underperformed the S&P 500. The biotech industry declined 9.3% compared with the S&P 500’s decline of 0.8%.
VVUS GLENMARK DB 532296 JNJ LGNZZ LGND LGNYZ LGNXZ LGNDZ BMRN GLKQY
Chicago, IL – June 4, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Illumina, Inc. (ILMN - Free Report) , Athersys, Inc. (ATHX - Free Report) , EyePoint Pharmaceuticals, Inc. (EYPT - Free Report) , Rhythm Pharmaceuticals, Inc.
NTLA EYPT UAA JBLU ILMN RYTM LGNDZ UA BRK.A ATHX LGNZZ LGND LGNYZ DG LGNXZ
Kitov Pharma Ltd. (KTOV - Free Report) announced today that the FDA has approved Consensi (amlodipine and celecoxib) oral tablets for the treatment of osteoarthritis pain and hypertension.
LGNZZ LGND LGNYZ LGNXZ HZNP PFE LGNDZ
Shares of Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) rose almost 8.2%, after the company announced that the FDA has accepted the new drug application (NDA) for its lead pipeline candidate, Firdapse, and granted Priority Review to the same. The FDA has set an action date of Nov 28, 2018.
CPRX ELY LGNZZ LGND LGNYZ LGNXZ ILMN LGNDZ BMRN
Melinta Therapeutics, Inc. (NASDAQ:MLNT) has 62 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 16,653,082 shares. Largest shareholders include Vatera Holdings Llc, Chelsea Counsel Co, Commonwealth Equity Services, Inc, Group One Trading, L.p., and Group One Trading, L.p.. Melinta Therapeutics, Inc.
LGNZZ LGNYZ LGND FH LGNXZ MLNT LGNDZ XSPA
Allergan plc (AGN - Free Report) announced a nationwide recall of some sample packs of Taytulla softgel oral contraceptive capsules (1mg/20mcg). Allergan said that four non-hormonal placebo pills were erroneously placed where the contraceptive capsules should have been. This instigated the recall following a physician report on the same.
WFC WFCNP WFC.WS WFC.PRL WFC.PRJ LGNDZ BMRN WFC.PRT WFC.PRR WFC.PRQ WFC.PRP AGN WFC.PRO WFC.PRN LGNZZ LGND LGNYZ LGNXZ WFC.PRY WFC.PRX WFC.PRW WFC.PRV
Shares of Prothena Corporation (PRTA - Free Report) were down 1.62% a day after the company announced a reorganization plan. Prothena’s stock has lost 67.3% in the last six months, worse than the industry’s decline of 7.8%.
DUKH LGNZZ CELG LGND LGNYZ LGNXZ DUK LGNDZ
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with SWEDISH ORPHAN (SWTUY - Free Report) and Ligand Pharmaceuticals (LGND - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
LGNZZ LGND LGNYZ LGNXZ ISRG LGNDZ TLRD
Dr. Reddy's Laboratories Ltd. (RDY - Free Report) reported fourth-quarter fiscal 2018 earnings per American Depositary Share (ADS) of 28 cents, down 3.5% from 29 cents earned in the year-ago quarter.
ENTA PVH RDY LGNZZ LGND LGNYZ LGNXZ UTX ILMN LGNDZ
Shares of Allergan plc (AGN - Free Report) have declined 4.4% since it reported its first-quarter 2018 results on Apr 30. In fact, so far this year, Allergan’s share price has declined 5.3%, compared with the industry’s decline of 6.8%.
AMGN TOL AGN LGNZZ LGND LGNYZ LGNXZ LGNDZ
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET